People On Street, Mexico

Media Advisories

Showing 1‐18 of 18

Lonza Announces First GMP Batch Completion at Next-Generation Mammalian Manufacturing Facility in Portsmouth (US)

First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US) State-of-the-art technology supports Lonza’s next-generation mammalian...

Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping...

Lonza Completes Expansion of New Drug Product Services Facility in Basel (CH)

Expansion adds a new facility to Lonza’s Drug Product Services (DPS) footprint, supporting clinical and commercial projects through additional quality control (QC) and...

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease

Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer’s disease Extension to...

Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH)

Expansion adds manufacturing capacity for clinical and commercial supply of microbially-produced biologics The facility is now GMP-qualified for manufacturing...

UK Government Supports Lonza’s Expansion Plans

Lonza has purchased a plot in Thames Valley Park, with a view to relocating and expanding its primary UK-based Biologics site over the next decade This proposed new site would...

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approved Sabirnetug is the first monoclonal antibody...

Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer

First time GMP manufacturing of a therapeutic IgE antibody has been achieved at scale GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC)...

Lonza and Oxford Nanopore to Collaborate on Novel Test to Accelerate Analysis of mRNA Products

Collaboration aims to commercialize a Current Good Manufacturing Practice (cGMP) validated test to enable advanced and innovative analysis for multiple critical quality...

Lonza Launches GS Effex® Cell Line for the Development of Therapeutic Antibodies with Increased Potency

New cell line designed to help overcome challenges in immunotherapy research and development related to the need for antibody therapeutics to have increased potency Derived...

Lonza and ABL Bio Collaborate in the Development and Manufacture of Bispecific Antibody Product

Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution Lonza’s DNA-to-IND program helps...

Lonza to Expand Early Development Services Offering into North America

A new facility in Cambridge, Massachusetts (US) will open in May 2023, making Lonza’s Early Development Services easily accessible to US-based customers New laboratories will...

Lonza Celebrates Groundbreaking of New Commercial Drug Product Facility in Stein

Milestone for the development of Lonza’s first large-scale drug product manufacturing facility based in Stein (CH) The facility will complete Lonza’s strategic commitment to...

Lonza Expands Manufacturing Collaboration With Asher Biotherapeutics to Include AB248, a Cis-Targeted IL-2 Immunotherapy

Asher Bio’s lead drug candidate AB248, a cis-targeted IL-2 immunotherapy for the treatment of cancer, to be manufactured at Lonza’s site in Visp (CH) Agreement builds upon...

Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering

Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox Collaborations further the development of an...

Lonza and Context Therapeutics Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being...

Lonza and Singzyme Announce Collaboration Agreement to Accelerate the Development of Bioconjugates

Collaboration Agreement to expand Lonza’s bioconjugation toolbox to include Singzyme’s site-selective conjugation technology

Lonza Collaborates with AbTis to Extend Bioconjugation Capabilities

Collaboration to implement AbTis’ AbClick® platform into Lonza’s bioconjugation toolbox